The European Medicines Agency recently launched a public consultation on a draft guideline for the notification of serious breaches of Regulation (EU) No 536/2014 or the clinical trial protocol. EIPG has reviewed the document and, following feedback from its members, has submitted its comments to the EMA.
-
-
News from EIPG
- Environmental sustainability: the EIPG perspective
- How AI is Changing the Pharma Industry and the Industrial Pharmacist’s Role
- Generative AI in drug development
- PGEU annual medicine shortages report
- EMA’s pilot scheme for academic and non-profit development of ATMPs
- Lessons learnt to transition from Horizon 2020 to the new FP10
- Approvals and flops in drug development in 2023